Eflornithine received approval from the US FDA as the first oral maintenance therapy for high-risk neuroblastoma. Credit: Kateryna Kon / Shutterstock.com.

Norgine has sought approval for eflornithine (difluoromethylornithine [DFMO]) for the treatment of patients with high-risk neuroblastoma (HRNB).

The development marks the first marketing authorisation applications submitted in Australia, Switzerland and the UK seeking approval for the drug.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The move is part of the Project Orbis initiative, aiming to expedite patient access to new treatment options.

Norgine has an exclusive licensing partnership with speciality pharmaceutical company US WorldMeds, under which Norgine will execute the registration and commercialisation activities of eflornithine in Europe, Australia and New Zealand.

Eflornithine received approval from the US Food and Drug Administration (FDA) as the first oral maintenance therapy for HRNB on 13 December 2023.

See Also:

It is indicated to reduce the relapse risk in adult and paediatric patients who have previously received therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA’s decision was informed by comparative results from the investigational arm of Study 3b and a clinical-trial-derived external control arm of Study ANBL0032.

The findings demonstrated that eflornithine treatment improved event-free survival and overall survival rates in patients with HRNB. These outcomes were notably better than those observed in patients treated with the standard of care without eflornithine.

Norgine chief medical officer Dr David Gillen stated: “These submissions via Project Orbis represent an important first step in the regulatory process for eflornithine and re-emphasise Norgine’s passion and commitment in attempting to secure additional treatment options for patients living with HRNB, a condition with a high level of unmet medical need.”

Last month, Norgine and Fennec Pharmaceuticals signed an exclusive licence agreement for the marketing of hearing loss therapy Pedmarqsi for paediatric cancer patients undergoing chemotherapy.